{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK4578/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1733.9093,"timestamp":1789415999999,"preClose":1707.2908,"halted":0,"volume":7286347,"delay":0,"changeRate":0.015591,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":26.61853,"latestTime":"09-14 16:00:00 EDT","open":1741.1221,"high":1752.0092,"low":1727.2628,"amount":1047569252.300261,"amplitude":0.014495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.281713,"peRate":46.44356,"turnoverRate":0.002359,"increases":2,"decrements":0,"flats":0,"marketCap":446853251072,"floatMarketCap":438562324480},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1752.0092,"amplitude":0.014495,"preClose":1707.2908,"low":1727.2628,"pbRate":"8.281713","latestPrice":1733.9093,"volume":7286347,"delay":0,"open":1741.1221,"prevYearClose":1612.5378,"prevWeekClose":1707.2908,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1911.2454,"twentyDayClose":1783.4272,"sixtyDayClose":1720.8374,"secType":"PLATE","market":"US","turnoverRate":0.002359,"peRate":46.44356,"marketCap":446853251072,"floatMarketCap":438562324480,"timestamp":1789415999999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664383293","title":"Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383293","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383293?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:51","pubTimestamp":1788252718,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday that phase 3 trials of remibrutinib showed significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.The trials met their primary endpoints and showed that remibrutinib was superior to teriflunomide on all key secondary measures.A preplanned combined analysis also showed a positive trend in three month confirmed disability progression and nominally significant results for six month confirmed disability progression, Novartis said.Remibrutinib also demonstrated a favorable safety profile with no liver safety signal, the company said.Novartis shares were over 4% higher in Tuesday premarket activity.Price: 158.47, Change: +6.41, Percent Change: +4.22","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4578","BK4588","NVS","BK4007","LU0320765489.SGD","IE00B2B36J28.USD","IE0002141913.USD","BK4585","LU0208291251.USD","LU0070302665.USD","MEDX","PPH","LU0211331839.USD","BK4532","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132713513","title":"Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=1132713513","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132713513?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:50","pubTimestamp":1788249011,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical giant Novartis AG (NVS.US) is experiencing a stark contrast in its neuro-immunology pipeline, as progress in one area is overshadowed by a serious setback in another. The company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","IE0002141913.USD","BK4532","BK4585","BK1574","BK4578","PSYK","IBBJ","BMED","MDTX","PPH","IE0009355771.USD","LU0208291251.USD","MEDX","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK1191","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4007","IE00BJT1NW94.SGD","IBBQ","BK4588","LU0211331839.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809308","title":"Novartis Pauses Autoimmune Cell Therapy Studies After Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809308?lang=en_us&edition=fundamental","pubTime":"2026-09-01 11:50","pubTimestamp":1788234600,"startTime":"0","endTime":"0","summary":"Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.The Swiss pharmaceutical company temporarily ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU2360032135.SGD","LU0321505868.SGD","IE0009355771.USD","LU0070302665.USD","BK4007","IE00BJT1NW94.SGD","LU0985481810.HKD","LU1032466523.USD","BK4532","BK4534","IE0002141913.USD","LU1670711040.USD","LU1670710661.SGD","LU1571399168.USD","LU1670710588.SGD","LU1236620834.HKD","IE00B4R5TH58.HKD","LU0061475181.USD","LU0208291251.USD","BK4559","IE00BFXG1179.USD","LU1093756168.USD","MEDX","LU1670711123.USD","LU1718418525.SGD","BK4581","LU0432979614.USD","LU2133065610.SGD","LU1868837136.USD","LU2596442595.SGD","LU0096364046.USD","NVS","LU1989771016.USD","LU0306807586.USD","BK4578","LU0882574055.USD","IHE","LU1261432733.SGD","LU1323610961.USD","LU2242646821.SGD","LU1883839398.USD","PPH","BMY","LU0321505439.SGD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0306806265.USD","FTXH","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002175","title":"Novartis AG Falls Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002175","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002175?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:15","pubTimestamp":1788192900,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.4% to CHF123.26 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 0.8% to 14,286.43.Novartis AG closed CHF8.24 below its 52-week high of CHF131.50, which the company reached on July 29, 2026.Trading volume was 2,544,960, compared to the 50-day average trading volume of 2,260,389.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4578","BK4588","BK4585","IE0002141913.USD","IE00BJT1NW94.SGD","LU0070302665.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE0009355771.USD","LU0211331839.USD","PPH","BK4007","NVS","MEDX","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":104,"code":"91000000","status":"200"}]}}